A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity-Reference-Cited by-同舟云学术

A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity

Published:2021-03-04 Issue:57 Volume:6 Page:
ISSN:2470-9468
Container-title:Science Immunology
language:en
Short-container-title:Sci. Immunol.

Author:

Boulch Morgane¹²^ORCID,Cazaux Marine¹²^ORCID,Loe-Mie Yann³^ORCID,Thibaut Ronan¹²,Corre Béatrice¹,Lemaître Fabrice¹,Grandjean Capucine L.¹^ORCID,Garcia Zacarias¹^ORCID,Bousso Philippe¹^ORCID

Affiliation:

1. Dynamics of Immune Responses Unit, Equipe Labellisée Ligue Contre le Cancer, Institut Pasteur, INSERM U1223, 75015 Paris, France.

2. University Paris Diderot, Sorbonne Paris Cité, Paris, France.

3. Hub de Bioinformatique et Biostatistique – Département Biologie Computationnelle, Institut Pasteur, Paris, France.

Abstract

A cross-talk involving CAR T cell–derived IFN-γ and host-derived IL-12 is essential to maintain CAR T cell killing potential in vivo.

Funder

H2020 European Research Council

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine,Immunology

Reference64 articles.

1. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

2. Chimeric Antigen Receptor Therapy

3. S. S. Neelapu F. L. Locke N. L. Bartlett L. J. Lekakis D. B. Miklos C. A. Jacobson I. Braunschweig O. O. Oluwole T. Siddiqi Y. Lin J. M. Timmerman P. J. Stiff J. W. Friedberg I. W. Flinn A. Goy B. T. Hill M. R. Smith A. Deol U. Farooq P. McSweeney J. Munoz I. Avivi J. E. Castro J. R. Westin J. C. Chavez A. Ghobadi K. V. Komanduri R. Levy E. D. Jacobsen T. E. Witzig P. Reagan A. Bot J. Rossi L. Navale Y. Jiang J. Aycock M. Elias D. Chang J. Wiezorek W. Y. Go Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma (2017); http://dx.doi.org/10.1056/NEJMoa1707447.

4. S. J. Schuster J. Svoboda E. A. Chong S. D. Nasta A. R. Mato Ö. Anak J. L. Brogdon I. Pruteanu-Malinici V. Bhoj D. Landsburg M. Wasik B. L. Levine S. F. Lacey J. J. Melenhorst D. L. Porter C. H. June Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas (2017); http://dx.doi.org/10.1056/NEJMoa1708566.

5. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL

Cited by 126 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive role and molecular biological function of proline-rich small repeat protein SPRR3 in the diagnosis of lung adenocarcinoma;International Journal of Biological Macromolecules;2024-10

2. CD4+ T cells in antitumor immunity;Trends in Cancer;2024-09

3. CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma;Nature Communications;2024-08-21

4. Mechanism of probiotics in the intervention of colorectal cancer: a review;World Journal of Microbiology and Biotechnology;2024-08-20

5. Complex association of body mass index and outcomes in patients with relapsed and refractory multiple myeloma treated with CAR-T cell immunotherapy;Cytotherapy;2024-08